Hims & Hers Health (NYSE:HIMS) Announces Earnings Results, Beats Expectations By $0.04 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings data on Monday. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.04, FiscalAI reports. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded down $0.16 during trading hours on Monday, reaching $15.47. 34,039,939 shares of the stock were exchanged, compared to its average volume of 26,693,072. Hims & Hers Health has a 52-week low of $15.15 and a 52-week high of $70.43. The stock has a market cap of $3.52 billion, a P/E ratio of 28.64, a P/E/G ratio of 2.92 and a beta of 2.43. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm’s 50 day moving average is $28.63 and its 200 day moving average is $40.27.

Hims & Hers Health declared that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. BTIG Research reduced their target price on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a report on Monday, February 2nd. TD Cowen decreased their price objective on Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating for the company in a report on Monday, February 9th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Evercore assumed coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft set a $31.00 price target on shares of Hims & Hers Health and gave the stock a “hold” rating in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $39.32.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider owned 169,940 shares in the company, valued at $6,238,497.40. The trade was a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 82,963 shares of company stock valued at $2,944,621. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Binnacle Investments Inc purchased a new stake in Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Silicon Valley Capital Partners acquired a new position in shares of Hims & Hers Health in the third quarter worth $48,000. EverSource Wealth Advisors LLC raised its holdings in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at $30,000. Finally, Greenline Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter valued at $36,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.